Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy

Trial Profile

Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Sep 2018

At a glance

  • Drugs HIV clades A C B DNA vaccine Inovio (Primary) ; INO 9012 (Primary) ; INO-6145 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 14 Aug 2018 According to an Inovio Pharmaceuticals media release, this trial is part of multi-year, dollar 6.95 million grant from the NIHs National Institute of Allergy and Infectious Diseases (NIAID) to develop a single or combination therapy using Inovios PENNVAX-GP with the goal of attaining long-term HIV remission.
    • 14 Aug 2018 According to an Inovio Pharmaceuticals media release, the first participant has been dosed in this trial.Results from this breakthrough study are expected in late 2019.
    • 03 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top